Encorafenib
B-Raf Serine-Threonine Kinase (Braf) Inhibitors
Sold as Braftovi
- Drug class
- B-Raf Serine-Threonine Kinase (Braf) Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 8
Overview
Encorafenib is an active pharmaceutical ingredient in the B-Raf Serine-Threonine Kinase (Braf) Inhibitors group (L01EC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | May 22, 2026 |
| EU European Union | EMA | 1 | November 5, 2025 |
| CA Canada | Health Canada | 1 | August 25, 2025 |
GBUnited Kingdom· MHRA
6 products
Uses
Melanoma Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Colorectal cancer (CRC) Encorafenib in combination with cetuximab is indicated for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.
Non-small cell lung cancer (NSCLC) Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
How to take
EUEuropean Union· EMA
1 product
Uses
Melanoma Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Colorectal cancer (CRC) Encorafenib in combination with cetuximab is indicated for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.
Non-small cell lung cancer (NSCLC) Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
How to take
CACanada· Health Canada
1 product
Side effects & warnings
, Ophthalmologic) • Grade 1-3 • If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold BRAFTOVI for up to 6 weeks. • If uveitis is Grade 1 and it improves to Grade 0, then resume at the same dose.
• If uveitis is Grade 2 or Grade 3 and it improves to Grade 0 or 1, then resume at a reduced dose. • If not improved, permanently discontinue BRAFTOVI plus binimetinib. • Grade 4 Permanently discontinue BRAFTOVI. QTc Prolongation (see 7.
Warnings and Precautions, Cardiovascular) • QTcF greater than 500 ms and less than or equal to 60 ms increase from baseline Withhold BRAFTOVI until QTcF less than or equal to 500 ms. Resume at reduced dose. • If more than one recurrence, permanently discontinue BRAFTOVI.
• QTcF greater than 500 ms and greater than 60 ms increase from baseline Permanently discontinue BRAFTOVI. Hepatotoxicity • Grade 2 AST or ALT increased Maintain BRAFTOVI dose. • If no improvement within 2 weeks, withhold BRAFTOVI until improves to Grade 0-1 or to pretreatment/baseline levels and then resume at same dose.
Drug interactions
Known interactions involving Encorafenib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 433. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB006030241 · revised May 22, 2026
- [2]European Medicines Agency · EMEA/H/C/004580 · revised November 5, 2025
- [3]Health Canada (DPD) · 02513099 · revised August 25, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.